News Related to Dual GIP/GLP-1 receptor agonist

Related coverage linked through entity extraction aliases.

Phase 3b trial reports positive results for Taltz-Zepbound psoriasis combo

May 13, 2026

Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.

Eli Lilly Advances Oral Obesity Drug Pipeline Amid Intensifying Market Competition

Feb 18, 2026

Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.